RR Donnelley (RRD) Misses Q4 EPS by 2c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus, FY19 EPS Mid-Point Guidance Below Consensus

RR Donnelley (NYSE: RRD) reported Q4 EPS of $0.64, $0.02 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $1.76 billion versus the consensus estimate of $1.74 billion.

“I am pleased to report that in 2018 we achieved our second consecutive year of improved organic sales performance and our highest annual organic sales growth since 2014. With both our Business Services and Marketing Solutions segments delivering organic growth for the year, we are demonstrating our unique ability to provide solutions to help our clients improve customer engagement and drive business performance. Throughout the year, we took significant steps to position RRD for the future, including realigning our organizational structure, executing significant cost reduction initiatives and repositioning our balance sheet in support of our strategic priorities. I am also excited that we concluded the year with a $115 million contract award for the 2020 U.S. Census work,” said Dan Knotts, President and Chief Executive Officer. “As we look to 2019, we have a solid client opportunity pipeline and our teams are aggressively implementing plans to address the inflationary cost headwinds that we expect to face throughout the year. We also plan to increase our investments in critical strategic initiatives, including new client implementations, as we continue to execute our strategy and further establish RRD’s position as a leading provider of marketing and business communications.”

GUIDANCE:

RR Donnelley sees FY2019 EPS of $0.60-$0.90, versus the consensus of $0.85. RR Donnelley sees FY2019 revenue of $6.5-6.7 billion, versus the consensus of $6.48 billion.

For earnings history and earnings-related data on RR Donnelley (RRD) click here.

You May Also Be Interested In

• Sandisk targets mid-to-high teens revenue growth through FY2030
• SEALSQ reports 120% revenue growth, signs key quantum deals
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance